Wells Fargo analyst Derek Archila lowered the firm’s price target on Monte Rosa Therapeutics to $17 from $18 and keeps an Overweight rating on the shares. The firm thinks shares remain cheap ahead of updated data for MRT-2359 and the determination of its RP2D. These are key de-risking catalysts in the second half of 2024, which Wells believes will drive shares higher.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics sees cash runway into 1H27
- Monte Rosa Therapeutics achieves milestones under Roche collaboration agreement
- Monte Rosa Therapeutics announces FDA acceptance of IND for MRT-6160
- Monte Rosa Therapeutics reports Q2 EPS (43c), consensus (54c)
- Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Questions or Comments about the article? Write to editor@tipranks.com